Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The molecule is currently undergoing a Phase 2 clinical study for obesity and type 2 diabetes (NCT05669599), with research findings expected to be updated by the end of 2024
International Journal of Colorectal Disease, 29(12), 1527-1534
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
Diabetes Care 42, 10271033
b , Structural superposition of the cryo-EM structure of GLP-1R NTD bound to GLP-1 to crystal structures of GIPR NTD bound to GIP (blue) and PTH1R NTD bound to PTH (cyan)
Studies have shown that GLP-1 receptor agonists are effective for preventing or managing obesity
US$ 27.23
US$ 25.02
US$ 29.85
US$ 22.61
US$ 29.06
US$ 22.68
US$ 27.31
US$ 21.94
